Tema ETFs’s Ascendis Pharma A/S ASND Stock Holding History

Tema ETFs’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-3,682	Closed	-$732K	–	566
2025 Q3	$732K	Sell	3,682 -396	-10%	-$73.9K	0.06%	310
2025 Q2	$704K	Sell	4,078 -2,028	-33%	-$330K	0.19%	120
2025 Q1	$952K	Sell	6,106 -12,934	-68%	-$1.85M	0.28%	92
2024 Q4	$2.62M	Buy	+19,040	New	+$2.5M	1.09%	31

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Tema ETFs's ASND Position: Q4 2025 in Review

Tema ETFs sold out of Ascendis Pharma A/S (ASND) in Q4 2025, closing a stake of 3,682 shares — an estimated $732K sold.

Tema ETFs first reported a position in ASND in Q4 2024 and held it in 4 quarters. The position peaked at $2.62M in Q4 2024. 302 funds tracked by Wall St. Rank hold ASND as of Q4 2025.

Tema ETFs reported no remaining Ascendis Pharma A/S position as of Q4 2025 after selling out during the quarter.
Tema ETFs sold 3,682 Ascendis Pharma A/S shares in Q4 2025, an estimated $732K.
Tema ETFs first reported a position in Ascendis Pharma A/S in Q4 2024 and held it in 4 quarters.
Tema ETFs's Ascendis Pharma A/S position peaked at $2.62M in Q4 2024.
302 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q4 2025.

Based on Tema ETFs's 13F filing for Q4 2025, filed 16 Jan 2026.